Loading
HKSEHealthcareBiotechnology
Latest quote
HK$9.45
−HK$0.60 · -5.97%
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Latest quote
HK$9.45
−HK$0.60 · -5.97%
Regular session · HKT · Market data may be delayed.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Day range
Current HK$9.45
52-week range
Current HK$9.45
Regular session · HKT · Market data may be delayed.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Day range
Current HK$9.45
52-week range
Current HK$9.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.03M CNY | 1.28M CNY | 56.6M CNY | 54.09M CNY | 76.88M CNY |
| Cost of goods sold | 1.5M CNY | 548K CNY | 30.61M CNY | 78.78M CNY | 37.7M CNY |
| Gross profit | 527K CNY | 735K CNY | 25.99M CNY | −24.69M CNY | 39.17M CNY |
| Research and development | 409.05M CNY | 302.39M CNY | 216.78M CNY | 267.1M CNY | 213.32M CNY |
| Selling, general, and administrative | 75.23M CNY | 101.74M CNY | 62.96M CNY | 32.41M CNY | 37.36M CNY |
| Operating expenses | 484.29M CNY | 296.15M CNY | 150.29M CNY | 319.29M CNY | 264.14M CNY |
| Interest income | 65.68M CNY | 91.99M CNY | 99.28M CNY | 44.16M CNY | 22.51M CNY |
| Interest expense | 164K CNY | — | 144K CNY | 157K CNY | 125K CNY |
| Depreciation and amortization | 12.89M CNY | 14.18M CNY | 18.48M CNY | 30.19M CNY | 29.55M CNY |
| Operating income | −483.76M CNY | −295.42M CNY | −300.21M CNY | −343.98M CNY | −224.97M CNY |
| Net income | −359.88M CNY | −300.94M CNY | −144.72M CNY | −314.84M CNY | −199.02M CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core MSCI Emerging Markets ETFIEMG3.03M0.00%162.15B USD0.09%$82.57+1.21%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM2.27M3.90%58.25M USD0.59%$31.1335-1.02%
State Street SPDR Portfolio Emerging Markets ETFSPEM915.21K0.01%17.86B USD0.07%$52.51+0.67%
iShares MSCI China Small-Cap ETFECNS119.31K0.18%63.98M USD0.59%$27.81-0.89%
iShares MSCI Emerging Markets Small-Cap ETFEEMS71.84K0.02%372.94M USD0.72%$76.365+0.84%
Avantis Responsible Emerging Markets Equity ETFAVSE51.01K0.02%229.94M USD0.33%$80.075+1.41%
State Street SPDR S&P China ETFGXC46.14K0.01%469.71M USD0.59%$87.58-0.21%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM7.7K0.00%1.74B USD0.09%$87.35+0.92%iShares Core MSCI Emerging Markets ETFIEMGRoundhill Investments - GLP-1 & Weight Loss ETFOZEMState Street SPDR Portfolio Emerging Markets ETFSPEMiShares MSCI China Small-Cap ETFECNSiShares MSCI Emerging Markets Small-Cap ETFEEMSAvantis Responsible Emerging Markets Equity ETFAVSEState Street SPDR S&P China ETFGXCState Street SPDR Portfolio MSCI Global Stock Market ETFSPGMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
